Bragar Eagel & Squire Issues Alerts Over Class‑Action Lawsuits vs. Skye Bioscience and Perrigo

On November 28, 2025, U.S. law firm Bragar Eagel & Squire, P.C. (BES) announced that class‑action lawsuits have been filed on behalf of shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE) and Perrigo Company plc (NYSE: PRGO), urging eligible investors to contact the firm if they wish to serve as lead plaintiffs. Skye Bioscience (SKYE) Class period spans November 4, 2024 to October 3, 2025. According to the complaint, Skye’s public statements misrepresented the effectiveness and prospects of its weight‑loss drug candidate, nimacimab. Specifically, the firm allegedly overstated nimacimab’s clinical, regulatory, and commercial potential, or failed to disclose data that undermined those claims. On October 6, 2025, Skye revealed Phase 2a trial results showing nimacimab monotherapy failed to meet its primary endpoint (weight loss vs placebo), and that drug exposure was lower than expected — possibly requiring higher dosing. Following the announcement, Skye’s share price plunged $2.85 per share (~60%), closing at $1.90 on October 6. Deadline for lead‑plaintiff applications: January 16, 2026. Perrigo (PRGO) Class period runs from February 27, 2023 to November 4, 2025. The lawsuit claims Perrigo failed to disclose major problems in its infant‑formula business — acquired from Nestlé — including underinvestment in maintenance, operational issues, manufacturing deficiencies, and underestimated remediation costs. On November 5, 2025, Perrigo reported disappointing Q3 results and cut its full‑year 2025 outlook, citing “infant formula industry dynamics.” The firm also initiated a strategic review of its infant‑formula operations and re-evaluated a previously announced $240 million investment, calling the segment “less strategic.” On that day, Perrigo’s stock price dropped $5.09 per share (–25.2%), closing at $15.10. Deadline for lead‑plaintiff applications: January 16, 2026. BES said it represents both individual and institutional investors in securities‑related litigation nationwide. Investors who purchased SKYE or PRGO shares during the respective class periods and suffered losses may have legal rights. Contact information and further details are available from the firm. #SkyeBioscience #Perrigo #ClassAction #InvestorAlert #SlimScan #GrowthStocks #CANSLIM